Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma

Author:

Ogura Michinori¹,Hatake Kiyohiko²,Ando Kiyoshi³,Tobinai Kensei⁴,Tokushige Kota⁵,Ono Chiho⁵,Ishibashi Taro⁵,Vandendries Erik⁶

Affiliation:

1. Department of Hematology and Oncology; Nagoya Daini Red Cross Hospital; Nagoya; Japan

2. Division of Medical Oncology and Hematology; Cancer Institute Hospital; Tokyo; Japan

3. Division of Hematology/Oncology; Department of Internal Medicine; Tokai University Hospital; Isehara; Japan

4. Hematology and Stem Cell Transplantation Division; National Cancer Center Hospital; Tokyo; Japan

5. Clinical Research; Pfizer Japan Inc; Tokyo; Japan

6. Pfizer Inc; Cambridge; Massachusetts; USA

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

Reference19 articles.

3. CMC-544 (inotuzumab ozogamicin): a CD22-targeted immunoconjugate of calicheamicin;DiJoseph;Hematol Meet Rep,2008

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献